Volume 22, Issue 3 (10-2019)
Hakim 2019, 22(3): 181-189 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohebati zehan T, Barzegar A, Najafikhah M. Legal Challenges of Encouraging Foreign Investment in Pharmaceutical Manufacturing. Hakim 2019; 22 (3) :181-189
URL: http://hakim.tums.ac.ir/article-1-1708-en.html
URL: http://hakim.tums.ac.ir/article-1-1708-en.html
1- Ph.D. student of Public Law, Maybod Branch, Islamic Azad University, Maybod, Iran.
2- Department of public Law, Maybod Branch, Islamic Azad University, Maybod, Iran. (Corresponding Author: reza.barzegar52@gmail.com )
3- Assistant Prof., Ministry of Health and Medical Education, Tehran, Iran.
2- Department of public Law, Maybod Branch, Islamic Azad University, Maybod, Iran. (Corresponding Author: reza.barzegar52@gmail.com )
3- Assistant Prof., Ministry of Health and Medical Education, Tehran, Iran.
Abstract: (2046 Views)
Legal Challenges of Encouraging Foreign Investment in Pharmaceutical Manufacturing
Taher Mohebati Zehan1*, Abdolreza Barzegar2, Mohsen Najafikhah3
1 PhD student of Public Law, Islamic Azad University, Meybod Branch, MD in Public Law.
2 Faculty Member of Islamic Azad University, Maybod Branch, Phd in Public Law.
3 Head of National Research Institute of Health Law, Phd in Private Law.
Abstract
Introduction: Due to Iran’s privileges to manufacture medicines and the capacity of the Middle East market, foreign investment in the pharmaceutical industry can be a solution for realizing the “General Policies of Resilient Economy” in the area of comprehensive and targeted support of exports and services.
Methods: In this study, for the first time, we used three steps to extract the permits and procedures required by foreign investment to take or pass in manufacturing drugs. The three steps included the collection of laws, codification to recognize valid from invalid regulations, and analyzing valid regulations in the area of foreign investment in manufacturing pharmaceutics. Besides reckoning, we examined the impacts of regulations on facilitating or impeding foreign investment.
Results: For investing in drug manufacturing, in addition to the legal requirement for obtaining permits and passing general procedures prescribed in the “Foreign Investment Promotion and Protection Act” (FIPPA), it is necessary to obtain special permits asserted in different laws and regulations. Therefore, the dispersion of rules and the multiplicity of permits and processes make it difficult to attract foreign capital. Under such circumstances, the obligation to release business licenses and the limitation of permits to issued cases set forth in the “Law of Implementation of General Policies of Principle (44) of the Constitution” cannot be effective.
Conclusion: To eliminate unnecessary procedures, licenses, and authorities, as well as to reduce the burden of scattered laws and regulations, solutions such as electronic permit issuance, codification of health code and strict implementation of article 7 of the “Law of Implementation of General Policies of Principle (44) of the Constitution” and articles 6 and 7 of FIPPA can be considered in policymaking in the health system.
Keywords: Pharmaceutical Industry; Health Policy; Investment; Legal Aspects; Unnecessary Procedures
*Corresponding Author: Ph.D. Student, Department of Public Law, Meybod Branch, Islamic Azad University, 10th Floor, No. 1, Next to the Derakhshan St., North Falamak Ave., Shahrak Gharb, Tehran, Iran. Tel: +98-2196881107, Email: ashoorijad@yahoo.com
Taher Mohebati Zehan1*, Abdolreza Barzegar2, Mohsen Najafikhah3
1 PhD student of Public Law, Islamic Azad University, Meybod Branch, MD in Public Law.
2 Faculty Member of Islamic Azad University, Maybod Branch, Phd in Public Law.
3 Head of National Research Institute of Health Law, Phd in Private Law.
Abstract
Introduction: Due to Iran’s privileges to manufacture medicines and the capacity of the Middle East market, foreign investment in the pharmaceutical industry can be a solution for realizing the “General Policies of Resilient Economy” in the area of comprehensive and targeted support of exports and services.
Methods: In this study, for the first time, we used three steps to extract the permits and procedures required by foreign investment to take or pass in manufacturing drugs. The three steps included the collection of laws, codification to recognize valid from invalid regulations, and analyzing valid regulations in the area of foreign investment in manufacturing pharmaceutics. Besides reckoning, we examined the impacts of regulations on facilitating or impeding foreign investment.
Results: For investing in drug manufacturing, in addition to the legal requirement for obtaining permits and passing general procedures prescribed in the “Foreign Investment Promotion and Protection Act” (FIPPA), it is necessary to obtain special permits asserted in different laws and regulations. Therefore, the dispersion of rules and the multiplicity of permits and processes make it difficult to attract foreign capital. Under such circumstances, the obligation to release business licenses and the limitation of permits to issued cases set forth in the “Law of Implementation of General Policies of Principle (44) of the Constitution” cannot be effective.
Conclusion: To eliminate unnecessary procedures, licenses, and authorities, as well as to reduce the burden of scattered laws and regulations, solutions such as electronic permit issuance, codification of health code and strict implementation of article 7 of the “Law of Implementation of General Policies of Principle (44) of the Constitution” and articles 6 and 7 of FIPPA can be considered in policymaking in the health system.
Keywords: Pharmaceutical Industry; Health Policy; Investment; Legal Aspects; Unnecessary Procedures
| Please cite this article as follows: Taher Mohebati Zehan, Abdolreza Barzegar, Mohsen Najafikhah. Legal Challenges of Encouraging Foreign Investment in Pharmaceutical manufacturing. Hakim Health Sys Res. 2019; 22(3): 181-189. |
*Corresponding Author: Ph.D. Student, Department of Public Law, Meybod Branch, Islamic Azad University, 10th Floor, No. 1, Next to the Derakhshan St., North Falamak Ave., Shahrak Gharb, Tehran, Iran. Tel: +98-2196881107, Email: ashoorijad@yahoo.com
Type of Study: Original |
Subject:
General
Received: 2017/07/15 | Accepted: 2020/02/24 | Published: 2020/02/24
Received: 2017/07/15 | Accepted: 2020/02/24 | Published: 2020/02/24
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
